David Zaccardelli Sells 46,888 Shares of Verona Pharma plc Stock
VRNA Stock | USD 39.63 0.27 0.68% |
About 76 percent of Verona Pharma's investors are selling. The analysis of overall sentiment of trading Verona Pharma PLC stock suggests that a fairly large number of investors are terrified at this time. The current market sentiment, together with Verona Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Verona Pharma PLC stock news signals to limit their universe of possible portfolio assets.
Verona |
Verona Pharma plc CEO David Zaccardelli sold 46,888 shares of the firms stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of 4.38, for a total transaction of 205,369.44. Following the sale, the chief executive officer now owns 15,298,896 shares in
Read at thelincolnianonline.com
Verona Pharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Verona Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Verona Pharma Fundamental Analysis
We analyze Verona Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verona Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verona Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Verona Pharma is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Verona Pharma PLC Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Verona Pharma stock to make a market-neutral strategy. Peer analysis of Verona Pharma could also be used in its relative valuation, which is a method of valuing Verona Pharma by comparing valuation metrics with similar companies.
Peers
Verona Pharma Related Equities
XFOR | X4 Pharmaceuticals | 11.43 | ||||
DAWN | Day One | 1.53 | ||||
MREO | Mereo BioPharma | 1.40 | ||||
IDYA | Ideaya Biosciences | 1.37 | ||||
SNDX | Syndax Pharmaceuticals | 1.27 | ||||
VTYX | Ventyx Biosciences | 1.13 | ||||
ABOS | Acumen Pharmaceuticals | 0.44 | ||||
MLTX | MoonLake Immunotherapeuti | 0.35 | ||||
AKRO | Akero Therapeutics | 0.22 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
APLS | Apellis Pharmaceuticals | 0.62 | ||||
MDGL | Madrigal Pharmaceuticals | 0.98 | ||||
TERN | Terns Pharmaceuticals | 1.58 | ||||
PTGX | Protagonist Therapeutics | 2.56 | ||||
VKTX | Viking Therapeutics | 2.88 | ||||
AMLX | Amylyx Pharmaceuticals | 3.48 |
Complementary Tools for Verona Stock analysis
When running Verona Pharma's price analysis, check to measure Verona Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verona Pharma is operating at the current time. Most of Verona Pharma's value examination focuses on studying past and present price action to predict the probability of Verona Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verona Pharma's price. Additionally, you may evaluate how the addition of Verona Pharma to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Transaction History View history of all your transactions and understand their impact on performance |